Endocanna Health Granted Patent For DNA Test That Could Prevent Weed-Related ER Visits

Endocanna Health, an industry leader in endocannabinoid system genomic testing, has been granted a first-of-its-kind U.S. patent for its DNA test, enabling hyper-personalized cannabinoid therapies based on user genetics.

The patent, "Graphical User Interfaces for Determining Personalized Endocannabinoid Genotypes and Associated Recommendations," describes novel methods for personalized endocannabinoid medicine.

The DNA test helps consumers avoid cannabis products that may cause negative health effects like cannabis-induced psychosis and rapid heart rate.

Objective: User’s Health

The objective is to prevent cannabis-related emergency room visits, which have significantly increased in states where cannabis is legal, especially among people over 65, which have shot up by 1,804% in California from 2005 to 2019. Similar increases have been seen in other places like Colorado and Ontario. 

“We are thrilled to receive the intellectual property protection for our comprehensive DNA test that is pioneering endocannabinoid compatibility," said Len May, CEO of Endocanna, emphasizing the importance of personalized cannabinoid therapeutics for better health outcomes. He also highlighted the need for personalized approaches, as everyone responds to cannabis consumption differently.

Patent Details: Endocanna's patented technology provides consumers with personalized insights into how cannabinoids interact with their genetics, guiding them toward formulations that offer better health outcomes. Using genetic data, the company recommends precise cannabinoid ratios, terpene combinations, and products aligned with individual profiles. The DNA report is supported by peer-reviewed studies and ongoing international clinical trials.

In addition to the granted patent, Endocanna has pending patents for proprietary cannabinoid formulations and an AI process that provides more precise therapeutic recommendations. The company's formulations are available in the U.S. and internationally through partner companies.

Endocanna's platform combines precision medicine and digital health, offering genetic insights, cannabinoid metabolism information, and personalized suggestions for cannabinoid therapies. The platform ensures user privacy and data protection in compliance with HIPAA regulations.

Related News

Endocanna Health Partners With We Decode To Help Veterans Obtain Personalized Cannabis

Canadian Study Raises Alarm About Cannabis Use During Pregnancy As ER And Hospital Visits Increase

Grandpa, Hold Off On The Weed: New Study Finds Alarming Trend Among Elderly

Image Credits: Amedeoemaja On Shutterstock Edited By Benzinga